Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Climb Bio, Inc.CLYM · Entity 5064 | Director | June 05, 2026 | June 08, 2026 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | EVP, Chief Commercial Officer | February 28, 2020 | February 29, 2020 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Director · President and CEO | January 29, 2026 | April 21, 2026 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | September 23, 2026 | September 25, 2026 |
| Vor Biopharma Inc.VOR · Entity 4763 | Director | June 11, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Climb Bio, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.55 · Expires 2036-06-04 | Direct | 40,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.
Sarepta Therapeutics, Inc.
Report date February 28, 2020 · Filed February 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,567 |
Reported balance
After 2020-02-28 transaction · row 1
1 source rowRow 1 · 2020-02-28 · Grant · Acquired 6,700 · Balance 8,567 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.47 · Expires 2030-02-28 | Direct | 37,500 |
Reported balance
After 2020-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-28 · Grant · Acquired 37,500 · Balance 37,500 F2: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy grantor retained annuity trust | 3,441 |
Reported balance
Holding disclosure · report date 2020-02-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,441 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date.
F2: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant.
Solid Biosciences Inc.
Report date January 29, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 169,401 |
Reported balance
After 2026-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-29 · Grant · Acquired 169,401 · Balance 169,401 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.
Stoke Therapeutics, Inc.
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.11 · Expires 2036-09-22 | Direct | 39,674 |
Reported balance
After 2026-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 39,674 · Balance 39,674 F1: The option award shall vest as to 1/12th of the total award quarterly on the 23rd calendar day of each December, March, June, and September, with the first tranche vesting on December 23, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award shall vest as to 1/12th of the total award quarterly on the 23rd calendar day of each December, March, June, and September, with the first tranche vesting on December 23, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.
Vor Biopharma Inc.
Report date June 11, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-10 | Direct | 56,345 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 56,345 · Balance 56,345 F1: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ra Pharmaceuticals, Inc.
Report date April 02, 2020 · Filed April 03, 2020
Section 16 reporting ended · disclosed 2020-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.88 · Expires 2029-06-11 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-04-02 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.99 · Expires 2028-11-14 | Direct | 0 |
Reported balance
After 2020-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-02 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.
F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
Verve Therapeutics, Inc.
Report date July 25, 2025 · Filed July 28, 2025
Section 16 reporting ended · disclosed 2025-07-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.02 | Direct | 0 |
Reported balance
After 2025-07-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-25 · Disposition to issuer · Disposed 136,139 · Balance 0 F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.73 | Direct | 0 |
Reported balance
After 2025-07-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-25 · Disposition to issuer · Disposed 42,200 · Balance 0 F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the "Effective Time"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration") (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the
F2: (continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2019 Filed Dec 18, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 2,727 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-061050 · doc4.xml · derivative · entry 7 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123 Underlying: Common Stock · 2,727 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 9,294 | $125.50 | $1,166,397.00 |
DisclosureSEC source: 0001209191-19-061050 · doc4.xml · nonDerivative · entry 5 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,867 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 32,706 | $125.50 | $4,104,603.00 |
DisclosureSEC source: 0001209191-19-061050 · doc4.xml · nonDerivative · entry 4 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,161 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 26,084 | $26.24 | $684,444.16 |
DisclosureSEC source: 0001209191-19-061050 · doc4.xml · nonDerivative · entry 3 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 3,895 | $13.71 | $53,400.45 |
DisclosureSEC source: 0001209191-19-061050 · doc4.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 2,727 | $13.71 | $37,387.17 |
DisclosureSEC source: 0001209191-19-061050 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 16:35 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantOption to Purchase Common Stock · Derivative | 15,000 | $0.00 Strike: $19.88 | $0.00 |
DisclosureSEC source: 0001104659-19-035366 · a4.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: On June 11, 2019, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the first anniversary of the grant date of June 11, 2019 or (ii) the Issuer's annual meeting of shareholders in 2020. Read SEC document |
| March 28, 2019 Filed Mar 29, 2019 23:59 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,165 | $118.68 | $256,942.20 |
DisclosureSEC source: 0001209191-19-021875 · doc4.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,161 F2 · price: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of performance-based restricted stock units. Read SEC document |
| March 28, 2019 Filed Mar 29, 2019 23:59 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 4,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021875 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,326 F1 · price: The transaction reflects the vesting of previously granted performance-based restricted stock units. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 01:06 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 45,000 | $0.00 Strike: $145.48 | $0.00 |
DisclosureSEC source: 0001209191-19-016038 · doc4.xml · derivative · entry 3 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-03-04 F2 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 01:06 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Disposition to issuerCommon Stock | 3,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016038 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,450 F1 · shares: Forfeiture of 3,375 shares of restricted stock due to performance goal not met. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:27 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 5,250 | $0.00 Strike: $26.24 | $0.00 |
DisclosureSEC source: 0001209191-19-006634 · doc4.xml · derivative · entry 5 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,965 Underlying: Common Stock · 5,250 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:27 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001209191-19-006634 · doc4.xml · derivative · entry 4 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:27 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 15,000 | $140.00 | $2,100,000.00 |
DisclosureSEC source: 0001209191-19-006634 · doc4.xml · nonDerivative · entry 3 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,266 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:27 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,250 | $26.24 | $137,760.00 |
DisclosureSEC source: 0001209191-19-006634 · doc4.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:27 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 2,250 | $13.90 | $31,275.00 |
DisclosureSEC source: 0001209191-19-006634 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| November 14, 2018 Filed Nov 15, 2018 16:34 UTC | Ra Pharmaceuticals, Inc. RARX · Entity 150034 | GrantOption to Purchase Common Stock · Derivative | 25,000 | $0.00 Strike: $12.99 | $0.00 |
DisclosureSEC source: 0001104659-18-068789 · a4.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-11-14 F1 · derivative.exercise_date: On November 14, 2018, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock. The option will vest and become exercisable in three equal installments on each of November 14, 2019, November 14, 2020 and November 14, 2021. Read SEC document |
| August 08, 2018 Filed Aug 8, 2018 22:16 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 6,000 | $121.02 | $726,120.00 |
DisclosureSEC source: 0001209191-18-045907 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,766 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of performance-based restricted stock award granted on September 19, 2016. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 11,914 | $13.90 Strike: $13.90 | $165,604.60 |
DisclosureSEC source: 0001209191-18-042389 · doc4.xml · derivative · entry 9 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 11,914 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 9,944 | $13.71 Strike: $13.71 | $136,332.24 |
DisclosureSEC source: 0001209191-18-042389 · doc4.xml · derivative · entry 8 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,895 Underlying: Common Stock · 9,944 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 11,924 | $13.71 Strike: $13.71 | $163,478.04 |
DisclosureSEC source: 0001209191-18-042389 · doc4.xml · derivative · entry 7 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,850 Underlying: Common Stock · 11,924 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 11,914 | $137.32 | $1,636,030.48 |
DisclosureSEC source: 0001209191-18-042389 · doc4.xml · nonDerivative · entry 6 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,766 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 11,914 | $13.90 | $165,604.60 |
DisclosureSEC source: 0001209191-18-042389 · doc4.xml · nonDerivative · entry 5 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 9,944 | $137.32 | $1,365,510.08 |
DisclosureSEC source: 0001209191-18-042389 · doc4.xml · nonDerivative · entry 4 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,766 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 9,944 | $13.71 | $136,332.24 |
DisclosureSEC source: 0001209191-18-042389 · doc4.xml · nonDerivative · entry 3 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 11,924 | $137.32 | $1,637,403.68 |
DisclosureSEC source: 0001209191-18-042389 · doc4.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,766 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 11,924 | $13.71 | $163,478.04 |
DisclosureSEC source: 0001209191-18-042389 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| May 22, 2018 Filed May 24, 2018 22:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionRestricted Stock Units · Derivative | 4,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033108 · doc4.xml · derivative · entry 3 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units and the second performance criterion was met on May 22, 2018, resulting in vesting of 25% of such restricted stock units. F3 · derivative.expiration_date: On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units and the second performance criterion was met on May 22, 2018, resulting in vesting of 25% of such restricted stock units. Read SEC document |
| May 22, 2018 Filed May 24, 2018 22:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,435 | $89.22 | $128,030.70 |
DisclosureSEC source: 0001209191-18-033108 · doc4.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,766 F2 · price: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 10, 2017. Read SEC document |
| May 22, 2018 Filed May 24, 2018 22:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 4,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-033108 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 1,370 | $0.00 Strike: $26.24 | $0.00 |
DisclosureSEC source: 0001209191-18-020351 · doc4.xml · derivative · entry 12 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,415 Underlying: Common Stock · 1,370 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 835 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001209191-18-020351 · doc4.xml · derivative · entry 11 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,001 Underlying: Common Stock · 835 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 54 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-18-020351 · doc4.xml · derivative · entry 10 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Underlying: Common Stock · 54 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 241 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-18-020351 · doc4.xml · derivative · entry 9 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,485 Underlying: Common Stock · 241 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 442 | $81.22 | $35,899.24 |
DisclosureSEC source: 0001209191-18-020351 · doc4.xml · nonDerivative · entry 8 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,325 F1 · shares: The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an "option swap" enables the exercise and holding of shares of Common Stock by the Reporting Person. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,370 | $26.24 | $35,948.80 |
DisclosureSEC source: 0001209191-18-020351 · doc4.xml · nonDerivative · entry 7 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 142 | $81.22 | $11,533.24 |
DisclosureSEC source: 0001209191-18-020351 · doc4.xml · nonDerivative · entry 6 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,397 F1 · shares: The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an "option swap" enables the exercise and holding of shares of Common Stock by the Reporting Person. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 835 | $13.90 | $11,606.50 |
DisclosureSEC source: 0001209191-18-020351 · doc4.xml · nonDerivative · entry 5 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 9 | $81.22 | $730.98 |
DisclosureSEC source: 0001209191-18-020351 · doc4.xml · nonDerivative · entry 4 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,704 F1 · shares: The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an "option swap" enables the exercise and holding of shares of Common Stock by the Reporting Person. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 54 | $13.71 | $740.34 |
DisclosureSEC source: 0001209191-18-020351 · doc4.xml · nonDerivative · entry 3 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 40 | $81.22 | $3,248.80 |
DisclosureSEC source: 0001209191-18-020351 · doc4.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,659 F1 · shares: The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an "option swap" enables the exercise and holding of shares of Common Stock by the Reporting Person. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:10 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 241 | $13.71 | $3,304.11 |
DisclosureSEC source: 0001209191-18-020351 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $71.45 | $0.00 |
DisclosureSEC source: 0001209191-18-017790 · doc4.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-03-05 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:38 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionRestricted Stock Units · Derivative | 9,752 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047895 · doc4.xml · derivative · entry 3 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. F3 · derivative.expiration_date: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:38 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 3,169 | $37.88 | $120,041.72 |
DisclosureSEC source: 0001209191-17-047895 · doc4.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,458 F2 · price: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:38 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 9,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-047895 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:45 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 2,500 | $13.71 Strike: $13.71 | $34,275.00 |
DisclosureSEC source: 0001209191-17-046035 · doc4.xml · derivative · entry 4 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,774 Underlying: Common Stock · 2,500 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:45 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 3,418 | $41.00 | $140,138.00 |
DisclosureSEC source: 0001209191-17-046035 · doc4.xml · nonDerivative · entry 3 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,875 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:45 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 2,500 | $41.00 | $102,500.00 |
DisclosureSEC source: 0001209191-17-046035 · doc4.xml · nonDerivative · entry 2 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,293 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:45 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 2,500 | $13.71 | $34,275.00 |
DisclosureSEC source: 0001209191-17-046035 · doc4.xml · nonDerivative · entry 1 Cumbo Alexander · CIK 0001685994 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.